You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
The firm is also pursuing advances in its manufacturing and ordering processes that it says will help it scale to $500 million in annual revenues.
Developed by researchers at Yale University, the method, called deterministic barcoding in tissue sequencing, can map thousands of genes at 10 micron resolution.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.
At the ASHG 2020 virtual meeting, researchers presented data showing they could use the method to enrich for placental DNA in maternal plasma samples.
Antibacterial and psychiatric drugs could counteract gene expression patterns seen in COVID-19, according to data presented at the virtual ASHG conference.
The firm's CLIA lab presented data at the virtual ASHG meeting showing how it validated WGS-based STR expansion analysis to diagnose rare disease.
Researchers from the Broad Institute and MIT have used RNA editing and single-cell RNA sequencing to record when RNA molecules were transcribed.
The new plate-based protocol developed at the Karolinska Institute combines low-coverage WGS and SMART-Seq2 transcriptomics for single-cells.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.